- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07606846
Exteriorization Versus In Situ Hysterotomy Repair During Cesarean: Effects on Uterine Tone
22. Mai 2026 aktualisiert von: Hannah Marie Kyllo, Stanford University
Uterine Exteriorization Versus In Situ Hysterectomy Repair During Cesarean Delivery: A Pilot Randomized Controlled Trial
During standard cesarean deliveries, there are two ways that obstetricians repair the incision on the uterus (hysterotomy after delivery of the baby.
One method involves lifting the uterus out of its regular place in the abdomen to repair the incision (uterine exteriorization for repair).
The second method involves leaving the uterus inside the abdomen to repair the uterus (in situ repair).
Both of these methods are regularly used by obstetricians during cesarean deliveries, and it is not currently known if one has benefits over the other.
Currently, surgeons use both methods, but lifting the uterus out of its place is slightly more common.
In this study, participants will be randomly assigned to have one of these techniques performed during their surgery.
Researchers will be investigating whether one technique or the other leads to better contraction of the uterus after delivery, less bleeding, less intra-operative nausea/vomiting, or a better patient experience than another.
Studienübersicht
Status
Noch keine Rekrutierung
Intervention / Behandlung
Detaillierte Beschreibung
There are two methods of uterine incision (hysterotomy) repair that can be utilized intra-operatively during a cesarean section: repair of the uterus within the abdomen (in situ) or temporary exteriorization of the uterus from the abdomen to repair the hysterotomy.
These two techniques have been previously compared in the literature, with outcomes that focus on intraoperative nausea/vomiting or blood loss measured as estimated blood loss or changes in hemoglobin.
Postpartum hemorrhage is the leading source of maternal morbidity and mortality worldwide.
Uterine atony, defined as inadequate uterine contraction to compress bleeding from the placental bed after delivery, is the leading cause of postpartum hemorrhage worldwide, accounting for upwards of 70% of cases.
Early assessments of and communication about uterine tone intra-operatively during cesarean deliveries are important for predicting and managing hemorrhage.
In a recent 2021 study, an 11-point (0 to 10) numeric rating scale for uterine tone, was shown to have strong interrater reliability and has since been implemented to assess uterine tone intra-operatively during cesarean sections at a number of institutions.
Low uterine tone scores have been found to be tightly correlated with postpartum hemorrhage and need for blood transfusion during hospitalization.
Uterine repair techniques have not yet been compared with regard to their impact on uterine tone intra-operatively, and this comparison may provide valuable information on how to optimize uterine tone through surgical technique, thereby decreasing the risk of hemorrhage and need for additional interventions.
The investigators propose a pilot randomized controlled trial comparing uterine exteriorization for hysterotomy repair versus in situ repair during cesarean sections.
The primary outcomes related to feasibility and acceptability will include: percent of patients approached who consented, percent of patients consented who obstetricians agreed to allow for randomization, and percent crossover from randomization arm.
The primary efficacy-related outcome will be uterine tone, as reported by the surgeon intra-operatively at multiple time points following delivery of the infant.
Secondary outcomes will include qualitative blood loss and use of medications to treat low uterine tone, intraoperative breakthrough pain, and nausea.
Studientyp
Interventionell
Einschreibung (Geschätzt)
60
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Hannah Kyllo M. Resident Physician, MD
- Telefonnummer: 650-723-5403
- E-Mail: hkyllo@stanford.edu
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Age 18-55
- Undergoing cesarean section
Exclusion Criteria:
- Patient age <18 or >55
- Case urgency deemed too great for consent
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Uterine Exteriorization
For participants randomized to the control group (uterine exteriorization for repair), standard technique for cesarean delivery will be performed intra-operatively.
At the time of hysterotomy repair, the uterus will be exteriorized from the abdomen and will be sutured closed in typical fashion.
Following closure of the hysterotomy, the uterus will be returned to the abdomen.
The remainder of the surgery will be performed with standard technique.
|
The uterus will be temporarily exteriorized from the abdomen for repair of the hysterotomy (uterine incision) after delivery of the infant in a cesarean section.
|
|
Experimental: In Situ Repair
For participants randomized to the experimental group (in situ repair), standard technique for cesarean delivery will be performed intra-operatively.
At the time of hysterotomy repair, the uterus will be left in situ and will be sutured closed in typical fashion.
The remainder of the surgery will be performed with standard technique.
|
Repair of the hysterotomy (uterine incision) within the abdomen (in situ) after delivery of the infant during a cesarean section.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Compliance/Feasibility
Zeitfenster: Duration of the study, approximately 2 years
|
Percentage of consented cesarean participants who were successfully treated as randomly allocated in each arm
|
Duration of the study, approximately 2 years
|
|
Efficacy Signal
Zeitfenster: Duration of the study, approximately 2 years
|
Mean quantitative blood loss, analyzed after log transformation in a regression model that adjusts for cesarean group (scheduled, 1st stage, and 2nd stage)
|
Duration of the study, approximately 2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility: Enrollment
Zeitfenster: Duration of the study, approximately 2 years
|
Number of consented participants who underwent cesarean section and Obstetrician agreed to randomization at huddle
|
Duration of the study, approximately 2 years
|
|
Incidence of Intraoperative Breakthrough Pain between groups
Zeitfenster: Duration of the study, approximately 2 years
|
Duration of the study, approximately 2 years
|
|
|
Incidence of Intraoperative Vomiting between groups
Zeitfenster: Duration of the study, approximately 2 years
|
Duration of the study, approximately 2 years
|
|
|
Total operative time between groups
Zeitfenster: Duration of the study, approximately 2 years
|
Measured in minutes from skin incision to closure
|
Duration of the study, approximately 2 years
|
|
Time from fetal delivery to hysterotomy closure between groups
Zeitfenster: Duration of the study, approximately 2 years
|
In minutes
|
Duration of the study, approximately 2 years
|
|
10 Minute Uterine Tone Score between groups
Zeitfenster: Duration of the study, approximately 2 years
|
Uterine tone score 10 minutes after delivery of the placenta between groups, measured on a scale of 0 to 10, with "0" representing "no tone" and "10" representing excellent tone.
|
Duration of the study, approximately 2 years
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Studienleiter: Jess Ansari, MD, MS, Stanford University
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juni 2026
Primärer Abschluss (Geschätzt)
1. Juni 2029
Studienabschluss (Geschätzt)
1. Juni 2029
Studienanmeldedaten
Zuerst eingereicht
19. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
19. Mai 2026
Zuerst gepostet (Tatsächlich)
26. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. Mai 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
22. Mai 2026
Zuletzt verifiziert
1. April 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Pathologische Prozesse
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Geburtsbedingte Geburtskomplikationen
- Schwangerschaftskomplikationen
- Blutung
- Puerperale Störungen
- Gebärmutterblutung
- Dystokie
- Pathologische Zustände, Anzeichen und Symptome
- Postpartale Blutung
- Uterusträgheit
Andere Studien-ID-Nummern
- 84585
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Beschreibung des IPD-Plans
No patient level data is anticipated to be shared with other researchers for future use after this study.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Kaiserschnitt
-
Heidelberg UniversityAbgeschlossenKopf-Hals-Karzinom | Frozen Section ManagementDeutschland
Klinische Studien zur Comparator Intervention: Exteriorization
-
Taipei Veterans General Hospital, TaiwanAbgeschlossenSubjektive GedächtnisbeschwerdenTaiwan
-
Children's Hospital Medical Center, CincinnatiNational Institutes of Health (NIH)Abgeschlossen
-
University of Massachusetts, WorcesterAbgeschlossen
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University Hospital und andere MitarbeiterAbgeschlossenAllergischer Schnupfen | Ganzjährige allergische Rhinitis | Nicht saisonale allergische RhinitisKorea, Republik von
-
Masimo CorporationAbgeschlossenAnästhesieVereinigte Staaten
-
Medline IndustriesBeendetChirurgieVereinigte Staaten
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); East Carolina UniversityAbgeschlossenDarmkrebsVereinigte Staaten
-
TeleflexRekrutierungPeripher eingeführter ZentralkatheterChina
-
Atea Pharmaceuticals, Inc.AbgeschlossenGesunde FreiwilligenstudieKanada
-
The Cleveland ClinicNational Institute on Drug Abuse (NIDA)Abgeschlossen